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Abstract 
 
The role of heterotopic (migratory) motoneurons (HMN) in the pathogenesis of spinal 
muscular atrophy (SMA) is still controversial. We examined the occurrence and 
amount of HMN in spinal cord tissue from eight children with SMA (six with SMA-I 
and two with SMAII). All affected subjects were carrying a homozygous deletion of 
exon 7 in the SMN1 gene. Unlike controls, virtually free from HMN, all SMA 
subjects showed a significant number of HMN at all levels of the spinal cord. 
Heterotopic neurons were hyperchromatic, located mostly in the ventral white matter 
and had no axon or dendrites. More than half of the HMN were very undifferentiated, 
as judged from their lack of immunoreactivity for NeuN and MAP2 proteins. Small 
numbers of more differentiated heterotopic neurons were also found in the dorsal and 
lateral white matter region. As confirmed by ultrastructural analysis, in situ end 
labeling (ISEL) and CD68 immunoreactivity, HMN in the ventral outflow were found 
to have no synapses, to activate microglial cells, and to eventually die by necrosis. An 
unbiased quantitative analysis showed a significant negative correlation between age 
of SMA subjects (a reflection of the clinical severity) and the number of HMN. 
Subjects who died at older ages had increased number of GFAP-positive astrocytes. 
Complementing our previous report on motoneuron apoptosis within the ventral horns 
in SMA, we now propose that abnormal migration, differentiation, and lack of axonal 
outgrowth may induce motoneuron apoptosis predominantly during early stages, 
whereas a slower necrosis-like cell death of displaced motoneurons which ‘‘escaped’’ 
apoptosis characterizes later stages of SMA. 
 
Keywords motoneurons, migration, pathogenesis, spinal muscular atrophy, SMN1 
gene 
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Introduction 
 
Spinal muscular atrophy (SMA) is the second most common neuromuscular disease 
after muscular dystrophy, the second most common autosomal recessive disease after 
cystic fibrosis, and the leading known genetic cause of infant mortality [3]. SMA is 
characterized by the loss of spinal cord anterior horn (AH) neurons, hypotonia, and 
progressive denervation of skeletal muscles [13]. According to age at onset and 
severity, SMA is classified in several types that form the clinical spectrum. In SMA-I 
(Werdnig–Hoffmann disease, acute SMA), onset is usually before 9 months. Affected 
infants fail to achieve early motor milestones and are never able to sit. Death occurs 
within the first 2 years of life, usually due to the respiratory failure. Survival in SMA-
I patients has increased in the recent years, in relation to better clinical care [36]. 
SMA-II is the intermediate or chronic infantile form, has an onset around 3–15 
months. Children with SMA-II may sit but do not learn to ambulate. SMA-III 
(Kugelberg–Welander disease) has an onset between 1 and 15 years. These children 
are able to achieve walking and generally live into adulthood. SMA-IV is a rare adult 
form with onset after 30 years of age. SMA-III and SMA-IV are sometimes difficult 
to separate from long-duration forms of pure lower motor variant of amyotrophic 
lateral sclerosis (ALS) [51]. 
   Nearly all SMA patients display homozygous deletions, rearrangements (gene 
conversions) or other mutations in the telomeric copy of the survival of motor neuron 
(SMN) gene on chromosome 5q13 [26]. Telomeric (SMN1) and centromeric (SMN2) 
genes differ by eight single nucleotide changes, two of which are in exons 7 and 8 
[38]. The exon 7 C-to-T transition at codon 280 has been shown necessary and 
sufficient for skipping of exon 7 during alternative splicing [29]. Consequently, about 
80–90% of SMN2 transcripts lack exon 7 and their dysfunctional protein product is 
insufficient to compensate for the loss of SMN1 protein [35]. Higher number of 
SMN2 copies (due to gene conversion events) has been linked to the less severe SMA 
types [14, 31]. However, as even diseased siblings with the same number of SMN2 
genes can have different SMA phenotypes, SMN locus itself cannot explain the 
genetic basis for phenotypic variability of SMA [12]. As many reports show, the 
clinical severity of the disease can be modified by the extent of deletion at SMN locus 
[5] encompassing other phenotypic modifier genes such as neuronal apoptosis 
inhibitory protein (NAIP) [40, 45] and H4F5 gene [23, 43]. 
   The SMN protein is a unique and poorly known molecule with many binding 
partners. SMN is found to be most abundant in the cytoplasm and nucleus of alpha 
motoneurons [1, 2, 53]. It is involved in various cellular processes, of which four 
seem to be best documented: assembly of spliceosomal small nuclear 
ribonucleoproteins (snRNPs) and pre-mRNA processing (splicing) [16], activation of 
transcription/translation [6], apoptosis [21, 22, 28, 42, 54], and axonal transport [2, 8, 
19, 34, 37, 39, 46]. Which of these functions is most important for the pathogenesis of 
SMA is not clear. 
   Together with the degeneration and loss of the AH cells (alpha and gamma 
motoneurons as well as interneurons), ‘‘empty cell beds’’ and glial cell bundles of 
ventral spinal roots that were originally described by Werdnig in [50], heterotopic 
(migratory) motoneurons (HMN) are postulated to be one of the hallmark 
neuropathological findings in SMA [9]. However, the importance of this phenomenon 
in the pathogenesis of SMA has been  largely neglected in both classical [24] and 
more contemporary studies [15, 33, 51]. Therefore, we re-examined the occurrence, 
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quantity, and ultrastructural morphology of HMN in children with clinically, 
pathologically, and genetically confirmed SMA. 
 
 
Materials and methods 
 
We investigated six children with SMA-I (three males, three females) and two 
children with SMA-II (two females), as well as five control subjects (two males, three 
females) who had no neurological disorder and died from either congenital heart 
disease or peritonitis. Five SMA-I and control cases were included in our previous 
study where we analyzed presence of apoptosis in gray matter of the AHs of the 
spinal cord [48]. The diagnosis of SMA was made on the basis of clinical findings 
(progressive muscle weakness and hypotonia), electromyoneurography, muscle 
biopsy, and was confirmed by genetic analysis of blood samples. Genotyping was 
performed using PCR amplifying exons 7 and 8 of the SMN1 gene, and exon 5 of the 
NAIP gene, as described previously [45, 48]. All eight affected subjects were carrying 
homozygous deletion of exon 7 in the SMN1 gene. Brain and muscle tissues were 
obtained at routine autopsies with informed consent from the families. Postmortem 
intervals varied from 4 to 7 h. 
   After formalin fixation, affected muscle tissue was stained using routine 
hematoxylin and eosin (H–E) staining. Following fixation in 4% formaldehyde in 
phosphate buffer saline (PBS, pH = 7.4) for several days to 4 weeks, each spinal cord 
was cut in the rostrocaudal direction in several slabs. Slabs were dehydrated through a 
graded series of ethanol solutions, cleared in toluene, embedded in paraffin 
(Histowax, Jung, Nussloch, Germany) and serially cut in 15-lm-thick sections. After 
deparaffinization in xylene, the sections were collected in 70% ethanol, put in 50% 
and then in 5% ethanol, then put in distilled water, and finally in a staining solution, 
which consisted of one part of 0.5% cresyl violet in distilled water mixed with four 
parts of distilled water. Upon achieving adequate staining, the sections were placed in 
distilled water, then dehydrated through a graded series of alcohol solutions and 
finally in ether–ethanol solution (two parts of ether and one part of 100% ethanol), 
rinsed with xylene, and mounted. 
   To confirm further that the observed heterotopic cells are truly neurons, we used 
NeuN and MAP2 immunocytochemistry. NeuN is a phosphoprotein that serves for 
identification of postmitotic neurons. Depending on the isoform (46 or 48 kDa), it can 
be localized either in the neuronal nuclei (in areas of low chromatin density) or in the 
neuronal cytoplasm [27]. MAP2 is a microtubuleassociated protein also specifically 
expressed in neuronal cells. To eliminate endogenous peroxidases and nonspecific 
staining, tissue sections were pretreated for 20 min in 0.3% hydrogen peroxide in the 
mixture of methanol and redistillated water (3:1), washed (3 9 10 min in PBS) and 
incubated with blocking solution (PBS containing 3% BSA and 0.5% Triton X-100, 
all from Sigma, St. Louis, MO, USA) for 2 h at room temperature. The sections were 
then incubated at 4ºC for 18 h with a monoclonal anti-neuronalnuclei antibody 
(NeuN, MAB377, clone A60, from Chemicon, Temecula, CA, USA) diluted in 
blocking solution (1:1,000) or anti-MAP2 antibody at 4ºC overnight (Sigma, St. 
Louis, MO, USA, diluted 1:1,000), washed again and incubated with secondary 
biotinylated antimouse antibody in blocking solution (1:200) for 1 h at room 
temperature (Vectastain ABC kit, Vector Laboratories, Burlingame, USA). Following 
another washing, the sections were incubated in Vectastain ABC reagent 
(streptavidin-peroxidase complex) for 1 h at room temperature and washed. Finally, 
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peroxidase activity was visualized using Ni-3,30-diaminobenzidine (DAB) (Sigma). 
In control sections, the primary antibody was omitted. The sections were washed in 
PBS, air-dried, dehydrated in a graded series of alcohol, cleared in xylene, and 
coverslipped with Histamount (National Diagnostics, Atlanta, GA, USA). 
Immunohistochemistry for glial fibrillary acidic protein (GFAP) was performed using 
an anti-cow GFAP monoclonal rabbit IgG (Dako, Copenhagen, Denmark) in dilution 
1:200, whereas macrophage/microglial marker CD68 was revealed using a rat anti-
mouse CD68 antibody (Serotec Ltd, Kidlington, Oxford, UK, cat. No. MCA1957) in 
1:80 dilution. Before immunohistochemistry, most slides were prestained with a Nissl 
stain to find which of them contained heterotopic neurons. Only those sections which 
contained HMN were destained from cresyl violet using graded alcohol solutions 
(from absolute to 50% solution and then phosphate buffer) and then incubated with 
primary antibodies. It should be noted that some of the cells, notably ependymal cells 
around the central canal, remained filled with cresyl-violet stain (purple color), which 
did not mix with specific immunoreactivity visualized by DAB (dark brown to black 
product) (as can be seen e.g., on Figs. 6 and 7). 
   For in situ end labeling (ISEL), sections were deparaffinized in xylene and hydrated 
to 50% ethanol in distilled water, preincubated with proteinase K (PK) buffer (10 mM 
Tris/HCl, 2.6 mM CaCl2, pH 7.0), and incubated with 5 µg/ml PK (Sigma, 
Zwijndrecht, The Netherlands),as described earlier [30, 48, 52]. Upon washing in 
distilled water, sections were incubated with terminal transferase (TdT) buffer (0.2 M 
sodium cacodylate, 0.025 M Tris/HCl in 0.25 mg/ml bovine serum albumine (BSA), 
pH 6.6) for 15 min at room temperature and then for 60 min at 37ºC with a reaction 
mixture that contained 0.2 ll TdT (terminal transferase) (Boehringer Mannheim, 
Almere, The Netherlands)/100 ll reaction mixture and 1.0 ll biotin-16-dUTP 
(Boehringer Mannheim)/100 ll reaction mixture and cobalt chloride (25 mmol; 5% of 
the final volume). Incorporation of labeled oligonucleotides was ended by rinsing the 
sections in distilled water and PBS. Endogeneous peroxidase activity was blocked 
with 0.01% H2O2 in PBS for 20 min at room temperature, after which the sections 
were washed in PBS, preincubated with PBS/1% BSA for 15 min, and incubated with 
peroxidase-conjugated avidin (ABC Elite kit, Vector Laboratories) 1:1000 in PBS/1% 
BSA overnight at 4ºC. Following washing in PBS, labeled DNA was visualized by 
incubation with 0.5 µg /ml diaminobenzidine (DAB) (Sigma) in 0.05 M Tris/HCl (pH 
7.5) with 0.02% H2O2 for exactly 12 min. Color development was stopped by 
washing in distilled water. Positive controls from rat prostate 3 days after castration 
were included in every assay [52]. 
   After fixation in 4% formaldehyde and 1.5% glutaraldehyde in PBS, selected slices 
of spinal cords were separated under a dissecting microscope and cut transversely on 
an ultramicrotome into semithin sections and stained with toluidine blue. Upon light-
microscopic examination, ultrathin sections were cut for electron microscopy. The 
sections were rinsed in 0.1 MNa–cacodylate buffer, postfixed at 4ºC for 2 h in 1% 
OsO4 in 0.1 M Na–cacodylate buffer, dehydrated in a graded series of ethanol, and 
embedded in LX112 acetone. The specimens were analyzed on a Philips 420 electron 
microscope at 80 kV. 
   Estimates of number of heterotopic (migratory) neurons were unbiasedly obtained 
by the physical disector method [20] using an Olympus Provis AX70 microscope 
equipped with a Nikon DXM 1200 camera attached to the computer. Upon a random 
start, every 6 and 7th section were systematically sampled and used for quantification. 
Statistical analysis was carried out using Statistica 7.0 software (StatSoft 2006, Tulsa, 
OK) and included Pearson’s coefficient of correlation and regression analysis. 
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   We investigated six children with SMA-I (3 males, 3 females) and two children 
with SMA-II (2 females), as well as five control subjects (2 males, 3 females) who 
had no neurological disorder and died from either congenital heart disease or 
peritonitis. Five SMA-I and control cases were included in our previous study where 
we analyzed presence of apoptosis in gray matter of the anterior horns of the spinal 
cord [46]. The diagnosis of SMA was made on the basis of clinical findings 
(progressive muscle weakness and hypotonia), electromyoneurography, muscle 
biopsy, and was confirmed by genetic analysis of blood samples. Genotyping was 
performed using PCR amplifying exons 7 and 8 of the SMN1 gene, and exon 5 of the 
NAIP gene, as described previously [43, 46]. All eight affected subjects were carrying 
homozygous deletion of exon 7 in the SMN1 gene. Brain and muscle tissues were 
obtained at routine autopsies with informed consent from the families. Postmortem 
time varied from 4 to 7 hours. 
   Upon formalin fixation, affected muscle tissue was stained using routine 
hematoxylin and eosin (H-E) staining. Following fixation in 4% formaldehyde in 
phosphate buffer saline (PBS, pH = 7.4) for several days to 4 weeks, each spinal cord 
was cut in the rostrocaudal direction in several slabs. Slabs were dehydrated through a 
graded series of ethanol solutions, cleared in toluene, embedded in paraffin 
(Histowax, Jung, Nussloch, Germany) and serially cut in 15-µm-thick sections. After 
deparaffinization in xylene, the sections were collected in 70% ethanol, put in 50% 
and then in 5% ethanol, then put in distilled water, and finally in a staining solution, 
which consisted of 1 part of 0.5% cresyl violet in distilled water mixed with 4 parts of 
distilled water. Upon achieving adequate staining, the sections were placed in distilled 
water, then dehydrated through a graded series of alcohol solutions and finally in 
ether-ethanol solution (2 parts of ether and 1 part of 100% ethanol), rinsed with 
xylene, and mounted. 
   To confirm further that the observed heterotopic cells are truly neurons, we used 
NeuN and MAP2 immunocytochemistry. NeuN is a phosphoprotein that serves for 
identification of postmitotic neurons. Depending on the isoform (46 or 48 kDa), it can 
be localized either in the neuronal nuclei (in areas of low chromatin density) or in the 
neuronal cytoplasm [26]. MAP2 is a microtubule-associated protein also specifically 
expressed in neuronal cells. To eliminate endogenous peroxidases and non-specific 
staining, tissue sections were pretreated for 20 min in 0.3% hydrogen peroxide in the 
mixture of methanol and redistillated water (3:1), washed (3 x 10 min in PBS) and 
incubated with blocking solution (PBS containing 3% BSA and 0.5% Triton X-100, 
all from Sigma, St. Louis, MO, USA) for 2 hours at room temperature. The sections 
were then incubated at 4°C for 18 hours with a monoclonal anti-neuronal-nuclei 
antibody (NeuN, MAB377, clone A60, from Chemicon, Temecula, CA, USA) diluted 
in blocking solution (1:1,000) or anti-MAP2 antibody at 4°C overnight (Sigma, St. 
Louis, MO, USA, diluted 1:1,000), washed again and incubated with secondary 
biotinylated anti-mouse antibody in blocking solution (1:200) for 1 hour at room 
temperature (Vectastain ABC kit, Vector Laboratories, Burlingame, USA). Following 
another washing, sections were incubated in Vectastain ABC reagent (streptavidin-
peroxidase complex) for 1 hour at room temperature and washed. Finally, peroxidase 
activity was visualized using Ni-3,3’-diaminobenzidine (DAB) (Sigma). In control 
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sections the primary antibody was omitted. The sections were washed in PBS, air-
dried, dehydrated in a graded series of alcohol, cleared in xylene and cover-slipped 
with Histamount (National Diagnostics, Atlanta, GA, USA). Immunohistochemistry 
for glial fibrillary acidic protein (GFAP) was performed using anti-cow GFAP 
monoclonal rabbit IgG (Dako, Copenhagen, Denmark) in dilution 1:200, whereas 
CD68 antigen was revealed using rat anti-mouse CD68 antibody from Serotec Ltd 
(Kidlington, Oxford, UK, cat. No. MCA1957) in 1:80 dilution. Before 
immunohistochemistry, most slides were pre-stained by Nissl stain to find which of 
them contain heterotopic neurons. Only those sections which contained HMN were 
destained from cresyl violet using graded alcohol solutions (from absolute to 50% 
solution and then phosphate buffer) and then incubated with primary antibodies. It 
should be noted that some of the cells, notably ependymal cells around the central 
canal, remained filled with cresyl-violet dye (purple color), which should not be 
mixed with specific immunoreactivity visualized by DAB (dark brown to black 
product) (as can be seen e.g. on Figs. 6 and 7). 
   For ISEL (in situ end labeling), sections were deparaffinized in xylene and hydrated 
to 50% ethanol in distilled water, preincubated with proteinase K (PK) buffer (10 mM 
Tris/HCl, 2.6 mM CaCl2, pH 7.0), and incubated with 5 µg/ml PK (Sigma, 
Zwijndrecht, The Netherlands), as described earlier [29, 46, 50]. Upon washing in 
distilled water, sections were incubated with terminal transferase (TdT) buffer (0.2 
sodium cacodylate, 0.025 M Tris/HCl in 0.25 mg/ml bovine serum albumine (BSA), 
pH 6.6) for 15 minutes at room temperature and then for 60 minutes at 37°C with a 
reaction mixture that contained 0.2 µl TdT (terminal transferase) (Boehringer 
Mannheim, Almere, The Netherlands)/100 µl reaction mixture and 1.0 µl biotin-16-
dUTP (Boehringer Mannheim)/100 µl reaction mixture and cobalt chloride (25 mmol; 
5% of the final volume). Incorporation of labeled oligonucleotides was ended by 
rinsing the sections in distilled water and PBS. Endogeneous peroxidase activity was 
blocked with 0.01% H2O2 in PBS for 20 minutes at room temperature, after which the 
sections were washed in PBS, preincubated with PBS/1% BSA for 15 minutes, and 
incubated with peroxidase-conjugated avidin (ABC Elite kit, Vector Laboratories) 
1:1000 in PBS/1% BSA overnight at 4°C. Following washing in PBS, labeled DNA 
was visualized by incubation with 0.5 µg/ml diaminobenzidine (DAB) (Sigma) in 
0.05 M Tris/HCl (pH 7.5) with 0.02% H2O2 for exactly 12 minutes. Color 
development was stopped by washing in distilled water. Positive controls from rat 
prostate 3 days after castration were included in every assay [50]. 
   After fixation in 4% formaldehyde and 1.5% glutaraldehyde in PBS, selected slices 
of spinal cords were separated under a dissecting microscope and cut transversely on 
an ultramicrotome into semi-thin sections and stained with toluidine blue. Upon light-
microscopic examination, ultra-thin sections were cut for electron microscopy. The 
sections were rinsed in 0.1 M Na-cacodylate buffer, postfixed at 4°C for 2 hours in 
1% OsO4 in 0.1 M Na-cacodylate buffer, dehydrated in a graded series of ethanol, and 
embedded in LX112 acetone. The specimens were analyzed on a Philips 420 electron 
microscope at 80 kV. 
   Estimates of number of heterotopic (migratory) neurons were unbiasedly obtained 
by the physical disector method [19] using an Olympus Provis AX70 microscope 
equipped with a Nikon DXM 1200 camera attached to the computer. Upon a random 
start, every 6th and 7th section were systematically sampled and used for 
quantification. Statistical analysis was carried out using Statistica 7.0 software 
(StatSoft 2006, Tulsa, OK) and included Pearson’s coefficient of correlation and 
regression analysis. 
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Results 
 
Affected muscle tissue showed typical pathological changes consistent with the 
diagnosis of SMA. In SMA-I and SMA-II subjects many sections contained HMN 
that were never observed in control subjects. Most of the heterotopic motoneurons 
were located outside the AH in the white matter of the anterior part of the spinal cord 
(ventral outflow) (Fig. 1a). They were almost always oval-shaped (undifferentiated) 
and without axonal or dendritic processes (Fig. 1b). In comparison to the motoneurons 
that remained in the gray matter of the AHs, which were always well-differentiated 
and frequently chromatolytic (‘‘ballooned motoneurons’’; Fig. 1c), the heterotopic 
motoneurons were never chromatolytic, but always more or less hyperchromatic 
(Figs. 1b, 2a, b, 3b; for more detailed microscopic and ultrastructural appearance of 
chromatolytic neurons see [48]). Majority of HMN were large or very large cells with 
diameter greater than 25 lm, while about 5–10% of the displaced cells had relatively 
small size—approximately three to five times smaller in crosssectional profile than 
large cells (e.g., several such cells can be seen on Fig. 6c). Many of the observed 
heterotopic motoneurons were found to accumulate at the anterior rim of the spinal 
cord (Figs. 2a, b, 6, 7). In some sections, particularly those of younger SMA subjects, 
we observed more than 10 heterotopic motoneurons aligned at the front wall of the 
spinal cord or outside the spinal cord (Fig. 2c). In Nissl-stained sections, some 
heterotopic motoneurons were found to strongly activate microglia-like cells (Figs. 
1b, 3b–d). Late stages of neuronophagia of HMN by activated microglia-like cells are 
illustrated in Fig. 3c and d. Sometimes the heterotopic motoneurons went far into the 
anterior spinal root (Fig. 4a–d). In these cases, activation of glial cells seemed to be 
even stronger (Fig. 4a–d). However, when taking into account all of the sections 
analyzed, degenerative changes of HMN and their heterophagic elimination were 
found to occur in a relatively small (\5%) proportion of the total population of the 
observed displaced neurons. Abnormally migrating cells were occasionally seen in the 
‘‘dorsal outflow,’’ dorsal to the Clarke’s column (Fig. 5a, b). Unlike HMN in the 
ventral outflow, which were always morphologically undifferentiated (i.e., without 
axon and dendrites), these heterotopic neurons were usually well differentiated (Fig. 
5c, d). Rarely, we also observed abnormally migrating neurons in the lateral part of 
the spinal cord which were even less numerous and more differentiated. 
   NeuN and MAP2 immunocytochemistry showed that less than a half of the 
heterotopic cells are matured neurons (Figs. 6 and 7). In contrast, nondisplaced 
neurons within the AHs demonstrated normal development and differentiation of 
dendritic structures (Fig. 7a, b). The numbers of NeuN and MAP2 immunolabeled 
heterotopic neurons varied from case-to-case and from slide-to-slide, but it was our 
impression that nearly 50% of HMN in the ventral white matter were NeuN-positive, 
whereas only about 25% were positive for MAP2 (Figs. 6 and 7). 
   Immunohistochemistry for macrophage/microglial marker CD68 confirmed our 
observations made on Nissl stained sections in that degenerated HMN were found to 
be eliminated by CD68-positive activated microglia cells (Fig. 8). It should be 
however noted that besides CD68-positive microglia directly involved in 
phagocytosis of HMN, there were often many positive cells along the pathway of 
abnormal migration of HMN (some of which are denoted by arrowheads in Fig. 8b 
and c). In controls, we did not find any CD68-positive cells except sporadically in 
association with blood vessels and within central canal (Fig. 8g). 
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   Unlike the situation within the ventral horns, where substantial quantities of ISEL-
positive microglial cells were regularly seen in close proximity to apoptotic and 
degenerating neurons (Fig. 9a, b), ISEL-positive microglial cells were also seen in the 
ventral outflow of the spinal cord (Fig. 9c). A few disintegrating HMN showed 
positive ISEL staining (Figs. 4e, 9d, e). However, because ISEL staining in fact 
recognizes DNA damage associated with both apoptosis and necrosis, on the basis of 
the morphological appearance (membrane breaks, cellular disintegration, prominent 
heterophagic elimination), we concluded that HMN are dying by a slow, necrotic type 
of cell death. 
   Immunoreactivity for GFAP showed large inter- and intrasubject variability. 
Together with astrocytes, in both normal controls and SMA subjects, GFAP staining 
was also associated with immunoreactivity of small size capillaries (with perivascular 
staining belonging to astrocytes). However, it was our general impression that SMA 
subjects differ from controls and among themselves in the following two ways. First, 
in contrast to normal controls, where GFAP immunoreactivity consisted of lightly and 
evenly distributed immunoreactivity of small astrocytes within the white matter fiber 
tracts, many sections from SMA subjects revealed the presence of medium and large 
astrocytes in close proximity to ‘‘empty cell beds’’ within the ventral horns of the 
spinal cord (Fig. 9f, g). Second, it appeared that subjects who died at an older age 
contained increased number of GFAP-positive astrocytes (Fig. 9h) (no quantification 
was made). We found no GFAP-positive astroglia around HMN (Fig. 9i). 
   Unlike control tissues, in which we were unable to demonstrate any necrotic 
motoneurons, electron microscopic analysis in materials from children with SMA 
revealed some oval shaped HMN in various stages of degeneration (Fig. 10a, b). The 
observed changes included breakdown of the plasma membrane, vacuolization of 
cytoplasmic organelles, and loss of structure, which are consistent with necrotic cell 
death type [10, 17]. In contrast to normal motoneurons, heterotopic motoneurons 
contained no ultrastructurally identifiable synapses. Microglial cells were seen in the 
vicinity of degenerating heterotopic motoneurons (Fig. 10a), as judged from their 
small size, irregular shape, and clumping of the chromatin along the inner side of the 
nuclear envelope. 
   Out of 3,307 sections sampled with physical disectors, 420 sections contained 
altogether 597 heterotopic motoneurons. The estimated total number of heterotopic 
motoneurons for each subject is shown in Fig. 11. The number of migratory 
motoneurons could be best described by an exponential regression equation: number 
of migratory motoneurons = 1240 * e0.07 * age in months. The quantitative results showed a 
significant negative correlation between age of SMA subjects (which is a reflection of 
the clinical severity of the disease), and the number of heterotopic motoneurons 
(Pearson’s coefficient of correlation r =-0.64, p = 0.04). 
 
 
Discussion 
 
Our results clearly demonstrate that a significant number of motor neurons in the 
spinal cord of children with SMA-I and SMA-II, but not in controls, aberrantly 
migrate toward the ventral spinal roots. Suprisingly, half or more of these HMN are 
very undifferentiated. Absence of proteins specific for matured neurons such as NeuN 
and MAP2 suggests ‘‘arrested’’ differentiation of HMN in a very early stage of 
development. To explore this issue further, doublestaining and expression of other 
markers of differentiation such as b-III-tubulin should be investigated. Most of HMN 
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are found to look morphologically healthy and remain present at the anterior rim of 
the spinal cord or within ventral spinal roots, while a very small proportion of these 
cells has been found in various stages of, presumably necrotic, degeneration. Since we 
observed just the endstage of the disease at autopsy, it is logical to assume that many 
more displaced cells were present in the tissue during earlier stages of the disease. 
Fewer but more differentiated migrating neurons are also present in the dorsal and 
lateral white matter region of the spinal cord. This finding contradicts most of the 
earlier studies, except perhaps that of Chou and Wang [9], and suggests that abnormal 
migration may underlie the pathogenesis of SMA. 
   We demonstrated previously apoptotic motoneuron death in a small proportion of 
the remaining spinal motoneurons in children with SMA-I [48]. As apoptotic neurons 
could be found only inside the gray matter of the AHs [48], we concluded that 
observed and here described abnormally migrated motoneurons somehow escaped 
apoptosis. Ultrastructural and ISEL analysis demonstrates that some of such 
heterotopic motoneurons in the spinal cord of children with SMA die by necrotic cell 
death [10, 17]. As postmortem delays were relatively short (4–7 h), we believe that 
the degenerative changes described were not caused by postmortem artifacts. 
Although phagocytosis is not limited to necrotic cells, given the non-controlled 
leakage of various cellular components into the neuropil during necrosis, one would 
expect that a phagocytic response may be more prominent and variable than when 
apoptosis or autophagic cell death occur, which are generally more silent and not 
expected to trigger a strong response. We therefore think that the necrotic mechanism 
of cell death is further supported by evidence of phagocytosis of necrotic HMN by 
microglial cells, which was confirmed by CD68 immunolabeling. 
   In our view, there are two possible explanations for finding of diffuse cytoplasmic 
ISEL staining of microglia in some sections (Fig. 9). First, in view of their role in 
phagocytosis, ISEL signal in the cytoplasm could represent the remnants of DNA of 
dying neighboring cells or neurons that had to be cleared and have been taken up by 
microglia. As such, this pattern does not necessarily confirm that the microglia cell 
itself is dying. Second, we do not know whether the cell death process of a microglia 
cell is identical to that of a neuron. Therefore, depending on the stage of the death 
process, fragmented DNA of the microglia cell nucleus itself can also leak into the 
cytoplasm, which is seen in some in vitro preparations and would explain the present 
pattern as well. Ultrastructural morphological features of activated microglial cells 
(irregular shape and clumping of the chromatin along the inner side of the nuclear 
envelope, Fig. 10) further suggest that these cells are undergoing apoptosis. Apoptosis 
in this case probably reflects a physiological mechanism by which excess amounts of 
microglial cells are eliminated. Our observation that AHs are usually more 
immunoreactive for GFAP than posterior horns is in accordance with increased 
content of GFAP found on two-dimensional electrophoretic gel from SMA-I spinal 
cord samples [4]. 
   It is difficult to estimate how many of the apoptotic motoneurons within the gray 
matter (see [48]) are actually dying due to aberrant migration, but we speculate that 
abnormal migration may induce motoneuron apoptosis of a small population of 
motoneurons within the gray matter in early stages of the disease and necrosis of a 
larger population of heterotopic motoneurons at later stages of SMA. In comparison 
to rapid intrauterine changes (presumably of apoptotic origin), these findings 
therefore imply a relatively slower mode of necrotic degeneration of displaced AH 
neurons after birth, in SMA children. Nevertheless, how exactly mutations in the 
SMA-determining gene SMN1 and other candidate disea
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protein products cause abnormal migration and cell death remains to be elucidated. 
The recent findings of interaction and translocation of SMN protein and b-actin 
mRNA to axons and growth cones [39] as well as the asymmetric SMN protein 
staining demonstrated in the germinative neuroepithelium [19] strongly support a 
specific role of SMN protein in motoneuron axonogenesis, migration, and 
differentiation. This role seems to be relevant for SMA pathogenesis, but independent 
of snRNP biosynthesis [8]. 
   Although deletions or mutations in the SMN1 gene are most highly correlated with 
SMA, it is not clear to what extent SMN2, NAIP or other genes influence the SMA 
phenotype, or whether some of SMA patients actually have functional copies of both 
SMN1 and NAIP. Due to the facts that large scale deletions and rearrangements of the 
5q13 region are specific for more severe (SMA-I) cases [5] and that we found a 
higher number of motoneurons undergoing abnormal migration in these cases, it is 
reasonable to speculate that in more severe SMA cases other genetic changes in the 
vicinity of SMN locus might influence the course of the disease. For example, it is not 
clear whether irregularly high transcription of the variable number of cadherin12 
pseudogenes in the SMN region somehow relates to the pathogenesis of SMA [44]. 
   As no sensory involvement can be found clinically, it is less widely recognized that 
the pathology of SMA may include cells other than those in the AHs. Namely, more 
subtle neuropathological changes in SMA have been already described in the lateral 
thalamic nucleus, cerebellar and brainstem nuclei, the nucleus of Clarke, and in dorsal 
root ganglia [32, 47]. Our observations of aberrant migration in the dorsal and lateral 
part of spinal cord white matter confirm and extend some of these earlier observations 
and support the idea that SMA is a multisystemic disease involving both motor and 
sensory systems. These, somewhat surprising, findings may be important for future 
molecular and cellular studies of this enigmatic disorder. 
   We believe that our results provide some key evidence for resolving important and 
unanswered questions from previous investigations. For example, in a classical work 
on glial cell bundles in SMA-I Ghatak concluded: ‘‘…The present observations 
suggest that such glial migration, although apparently unique in Werdnig–Hoffmann 
disease, is a secondary phenomenon and fails to resolve the issue as to whether 
neuronal degeneration or an injury to the nerve roots is the primary event in this 
disorder’’ [18]. On the basis of our findings described here, we think that abnormal 
migration is the primary pathogenetic event in SMA, which causes (attracted) glial 
cells to follow displaced neurons thus forming glial cell bundles of ventral spinal 
roots. In fact, abnormal migration may be responsible for all major neuropathological 
features of SMA, including the loss of the AH cells and ‘‘empty cell beds.’’ 
   Similarly to SMA, there is a still ongoing controversy regarding the origin, 
presence, and role of HMN in the spinal cord of ALS patients [25, 33, 41]. Besides 
families in which SMA and ALS coexist [7], it has been shown that SMN genotypes 
that produce less SMN protein [49] or have different SMN1 gene copy numbers [11] 
increase the risk of sporadic ALS or duration of ALS evolution. In this context, the 
findings described in the present study may also be relevant for future research on 
heteterotopic neurons in the pathogenesis of ALS. 
   In conclusion, we convincingly demonstrated, albeit in a relatively small number of 
SMA subjects, that abnormal migration, differentiation, and axon outgrowth may 
represent pathogenetic mechanisms of this devastating disease. However, how exactly 
mutations in SMA gene SMN1 and other disease-modifying genes and their protein 
products prevent motoneuron axonogenesis and cause aberrant migration remains to 
be elucidated. Given some possible genetic interactions between SMA and the risk for 
 12 
developing ALS, our findings may also bear considerable relevance for future 
research on axonopathy and heterotopic neurons in the pathogenesis of ALS. 
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Figure legends 
 
Fig. 1 (a) Abnormally heterotopic (migratory) motoneurons (HMN) can be found in 
SMA subjects all along the ‘‘ventral outflow,’’ from the anterior horn (AH) to the 
ventral root (VR). Cresyl-violet stain. (b) Higher magnification of the frame in a. 
Heterotopic neurons were always undifferentiated (oval shaped), without visible axon 
and dendrites. Cresyl-violet stain. (c) A chromatolytic (ballooned) motoneuron (bmn) 
from the gray matter of AH of the same SMA-I subject for comparison with b. Note 
the well-developed neuronal processes (arrows). Cresyl-violet stain. Scale bars: (a) 
200 µm; (b, c) 20 µm 
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Fig. 2 (a, b) Accumulation of heterotopic (migratory) motoneurons (HMN, mmn) at 
the anterior rim of the spinal cord. AH, anterior horn, VR, ventral root. Cresyl-violet 
stain. (a) Female five-month-old SMA-I subject. (b) Male eightmonth- old SMA-I 
subject. (c) In some sections, particularly those of younger SMA-I subjects, we 
observed more than 10 heterotopic motoneurons ‘‘aligned’’ at the front wall of the 
spinal cord (lower left corner arrow) or outside the spinal cord (lower right corner 
arrow). Scale bars = 20 µm 
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Fig. 3 (a) Two oval-shaped hyperchromatic heterotopic (migratory) motoneurons 
(HMN, mmn) at the anterior rim of the spinal cord of SMA-I subject. VR, ventral 
root; AH, anterior horn. Cresyl-violet stain. (b) Higher magnification of the frame in 
a. Note activated microglial cells around and ‘‘behind’’ (i.e., along the migrational 
route) the heterotopic motoneurons (arrows). Cresyl-violet stain. (c, d, e) 
Neuronophagia of heterotopic motoneurons by glial cells. Cresyl-violet stain. Scale 
bars: (a) 200 µm; (b–e) 20 µm 
 
 
 20 
Fig. 4 (a) Two wandering motoneurons making their way out of the spinal cord and 
three more at the anterior rim of the spinal cord of a child with SMA-I. VR, ventral 
root, AH, anterior horn. Cresyl-violet stain. (b) Higher magnification of the frame in 
a. (c) Pronounced neuronophagia of heterotopic motoneurons (arrows), particularly 
within the ventral spinal root (VR) of a SMA-I subject. Cresyl-violet stain. (d) 
Detached ventral root (VR) containing three heterotopic (migratory) motoneurons 
(HMN, mmn) within glial cell bundles (GB). (e) Five HMN, two of which seem to 
degenerate (arrows). Cresyl-violet stain. Scale bars: (a) 200 µm; (b–e) 20 µm 
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Fig. 5 (a) Two abnormally migrating cells (arrows) dorsal to the thoracic nucleus (NT, 
Clarke’s column) in a SMA subject. (b) Higher magnification of the frame in a. (c, d) 
Relatively welldifferentiated Heterotopic neurons in the ‘‘dorsal outflow’’ (arrows). 
Cresyl-violet stain. Scale bars: (a–d) 200 µm 
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Fig. 6 NeuN immunocytochemistry of several SMA-I and SMA-II subjects (a–f). 
Note that all slides were prestained by cresyl-violet (therefore, some of the cells, 
mostly ependymal glial cells around the central canal remained filled with cresyl-
violet and have a purple color, identifiable from the specific NeuN staining visualized 
by DAB (dark brown to black color). About a half of heterotopic motoneurons at the 
anterior rim of the spinal cord were NeuN-positive (arrows), the other half were not 
(arrowheads). Scale bars: 200 µm 
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Fig. 7 MAP-2 immunocytochemistry of two SMA-I cases (a–e) and one control (f). 
Panel b shows the upper inset from a and shows two MAP2-positive (dark-brown 
DAB product) neurons within anterior horn (arrows), c is lower inset from a and 
shows five MAP2-negative heterotopic neurons (arrowheads); one more is illustrated 
in e (arrowhead). Arrows in d show four MAP2-positive HMN. Summarizing all 
analyzed slides from eight SMA subjects together, only about 1/3 of the observed 
HMN were positive for MAP2 protein. Scale bars: (a, d, e) 500 µm; (b, f) 50 µm; (c) 
100 µm 
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Fig. 8 CD68 immunohistochemistry. (a) Nissl stain of several HMN before CD68 
immunohistochemistry. (b) Same slide after CD68 immunohistochemistry. Several 
CD68 immunoreactive activated microglial cells in the vicinity of HMN at the 
anterior rim of the spinal cord of SMA subject are shown by arrows. (c, e) Two 
representative pictures of CD68-positive microglial cells. Arrows in c show three 
microglial cells attached to heterotopic (migratory) motoneuron. (d) Inset of c, a 
microglial cell (arrowhead) better seen in another optical plane. Arrowheads in e 
show several CD68-positive microglia cells along the migrational route of HMN. (f) 
Heterophagic elimination of HMN by several CD68-positive activated microglial 
cells. Note disintegration of HMN and loss of tigroid substance (rough endoplasmic 
reticulum). (g) Control spinal cord. Only CD68-positive microglia associated with 
blood vessels could be occasionally seen (arrowhead). (h) Positive control showing 
many CD68-positive activated microglial cells (rat prostate). Scale bars = 20 µm 
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Fig. 9 In situ end-labeling (ISEL). Sections are lightly counterstained with methyl 
green. Control sections of spinal cord had no ISEL-positive cells, except occassional 
vascular microglia (not shown). Although activation of microglial cells was more 
frequently seen within the anterior horns of SMA patients, where ISEL-positive 
microglia phagocytized apoptotic and degenerating motoneurons (a and b), ISEL-
positive microglia were also seen in the anterior white matter of SMA subjects. 
Apoptosis of these microglial cells is probably associated with their demise upon 
elimination of HMN (c). Small arrowheads show ISEL-positive microglia, large 
arrowheads show ISEL-positive neurons. Note that ISEL labeling of microglial nuclei 
is often more intensive than of the cytoplasm, e.g., ISELpositive microglial cell in the 
lower right corner in a. (d) ISELpositive necrotic HMN at the anterior rim of the 
spinal cord of SMA-I subject. (e) inset from d at higher magnification. This was a 
relatively rare finding since most of the HMN were looking morphologically healthy 
and were not ISEL-positive. (f) Immunoreactivity for GFAP showed large inter- and 
intrasubject variability in SMA patients. The anterior horns were however 
consistently more immunoreactive for GFAP than posterior horns, as shown in f. In 
contrast to controls, where GFAP immunoreactivity consisted of lightly and evenly 
distributed immunoreactivity of small astrocytes within the white matter fiber tracts, 
many sections from SMA subjects revealed the presence of medium and large 
astrocytes in close proximity to ‘‘empty cell beds’’ within the ventral horns of the 
spinal cord (g). Subjects who died at an older age had high numbers of GFAP-positive 
astrocytes (h, not quantified). We found no GFAP-positive astroglia around HMN (i). 
AH, anterior horn; VR, ventral root. Scale bars: (a, b, e, h, i) 20 µm; (c, d, f) 200 µm; 
(g) 10 µm 
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Fig. 10 (a) Electron microscopic appearance of a heterotopic motoneuron. 
Ultrastructural changes include breakdown of the plasma membrane, dilation and 
vacuolization of cytoplasmic organelles and loss of structure, which are all consistent 
with necrotic cell death (type 3b according to classification of Clarke [9]). In contrast 
to normal motoneurons, heterotopic motoneurons contained no identifiable synapses. 
In the lower left corner is an apoptotic microglial cell (arrow), as judged from its 
small size and clumping of the chromatin along the inner side of the nuclear envelope. 
(b) Another heterotopic motoneuron in relatively late stage of necrotic degeneration 
with dilation and rupture of most of the cytoplasmic organelles. Arrow shows an 
apoptotic microglial cell in the lower right corner. Scale bars: (a, b) 1 µm 
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Fig. 11 Number of heterotopic motoneurons found in the spinal cords of six SMA-I 
(circles) and two SMA-II subjects (squares). There was a statistically significant 
negative correlation between thenumber of heterotopic neurons and age (r = -0.64, 
p=0.04) 
 
 
 
 
